To the editor

Ravindranath Tiruvoipati; Giles Peek

doi:10.1001/jama.2021.20996

To the editor

Ravindranath Tiruvoipati, Giles Peek

Research output: Contribution to journal › Letter › Other › peer-review

Original language	English
Pages (from-to)	83-84
Number of pages	2
Journal	JAMA
Volume	327
Issue number	1
DOIs	https://doi.org/10.1001/jama.2021.20996
Publication status	Published - 4 Jan 2022
Externally published	Yes

Access to Document

10.1001/jama.2021.20996

Cite this

@article{1f7d81c2f671435285174cca44d82a48,

title = "To the editor",

author = "Ravindranath Tiruvoipati and Giles Peek",

note = "Funding Information: Author Affiliations: Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, Northern Ireland (McNamee); Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York (Brodie); Wellcome-Wolfson Institute for Experimental Medicine, Queen{\textquoteright}s University Belfast, Belfast, Northern Ireland (McAuley). Corresponding Author: Daniel F. McAuley, MD, Wellcome-Wolfson Institute for Experimental Medicine, Queen{\textquoteright}s University Belfast, 97 Lisburn Rd, Belfast BT9 7BL, Northern Ireland (d.f.mcauley@qub.ac.uk). Conflict of Interest Disclosures: Dr McNamee reported receiving grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme during the conduct of the study and receiving speaking fees from Baxter. Dr Brodie reported receiving grants from ALung Technologies and personal fees from Xenios, Abiomed, Medtronic, and Cellenkos and being the chair of the executive committee of the International ECMO Network. Dr McAuley reported receiving grants from the NIHR HTA Programme during the conduct of the study; receiving personal fees from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Eli Lilly, and Vir Biotechnology and grants from the NIH, the Wellcome Trust, Innovate UK, the Medical Research Council, and the Northern Ireland Health and Social Care Research and Development Division; having a patent issued by Queen{\textquoteright}s University Belfast for a novel treatment for inflammatory disease (US8962032); and being codirector of research for the Intensive Care Society and NIHR/ Medical Research Council Efficacy and Mechanism Evaluation Programme. 1. McNamee JJ, Gillies MA, Barrett NA, et al; REST Investigators. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. JAMA. 2021;326(11):1013-1023. doi:10.1001/jama.2021.13374 2. van Haren F, Pham T, Brochard L, et al; Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure Investigators. Spontaneous breathing in early acute respiratory distress syndrome: insights from the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure Study. Crit Care Med. 2019;47(2):229-238. doi:10. 1097/CCM.0000000000003519 3. Kalbhenn J, Neuffer N, Zieger B, Schmutz A. Is extracorporeal CO2 removal really “safe” and “less” invasive? observation of blood injury and coagulation impairment during ECCO2R. ASAIO J. 2017;63(5):666-671. doi:10.1097/MAT. 0000000000000544 4. Lockie CJA, Gillon SA, Barrett NA, et al. Severe respiratory failure, extracorporeal membrane oxygenation, and intracranial hemorrhage. Crit Care Med. 2017;45(10):1642-1649. doi:10.1097/CCM.0000000000002579 5. Boyle AJ, Sklar MC, McNamee JJ, et al; International ECMO Network. Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future. Lancet Respir Med. 2018;6(11):874-884. doi:10.1016/S2213-2600(18)30326-6 6. Fitzgerald M, Millar J, Blackwood B, et al. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care. 2014;18(3):222. doi:10.1186/cc13875",

year = "2022",

month = jan,

day = "4",

doi = "10.1001/jama.2021.20996",

language = "English",

volume = "327",

pages = "83--84",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association (AMA)",

number = "1",

}

TY - JOUR

T1 - To the editor

AU - Tiruvoipati, Ravindranath

AU - Peek, Giles

N1 - Funding Information: Author Affiliations: Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, Northern Ireland (McNamee); Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York (Brodie); Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, Northern Ireland (McAuley). Corresponding Author: Daniel F. McAuley, MD, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, 97 Lisburn Rd, Belfast BT9 7BL, Northern Ireland (d.f.mcauley@qub.ac.uk). Conflict of Interest Disclosures: Dr McNamee reported receiving grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme during the conduct of the study and receiving speaking fees from Baxter. Dr Brodie reported receiving grants from ALung Technologies and personal fees from Xenios, Abiomed, Medtronic, and Cellenkos and being the chair of the executive committee of the International ECMO Network. Dr McAuley reported receiving grants from the NIHR HTA Programme during the conduct of the study; receiving personal fees from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Eli Lilly, and Vir Biotechnology and grants from the NIH, the Wellcome Trust, Innovate UK, the Medical Research Council, and the Northern Ireland Health and Social Care Research and Development Division; having a patent issued by Queen’s University Belfast for a novel treatment for inflammatory disease (US8962032); and being codirector of research for the Intensive Care Society and NIHR/ Medical Research Council Efficacy and Mechanism Evaluation Programme. 1. McNamee JJ, Gillies MA, Barrett NA, et al; REST Investigators. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. JAMA. 2021;326(11):1013-1023. doi:10.1001/jama.2021.13374 2. van Haren F, Pham T, Brochard L, et al; Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure Investigators. Spontaneous breathing in early acute respiratory distress syndrome: insights from the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure Study. Crit Care Med. 2019;47(2):229-238. doi:10. 1097/CCM.0000000000003519 3. Kalbhenn J, Neuffer N, Zieger B, Schmutz A. Is extracorporeal CO2 removal really “safe” and “less” invasive? observation of blood injury and coagulation impairment during ECCO2R. ASAIO J. 2017;63(5):666-671. doi:10.1097/MAT. 0000000000000544 4. Lockie CJA, Gillon SA, Barrett NA, et al. Severe respiratory failure, extracorporeal membrane oxygenation, and intracranial hemorrhage. Crit Care Med. 2017;45(10):1642-1649. doi:10.1097/CCM.0000000000002579 5. Boyle AJ, Sklar MC, McNamee JJ, et al; International ECMO Network. Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future. Lancet Respir Med. 2018;6(11):874-884. doi:10.1016/S2213-2600(18)30326-6 6. Fitzgerald M, Millar J, Blackwood B, et al. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care. 2014;18(3):222. doi:10.1186/cc13875

PY - 2022/1/4

Y1 - 2022/1/4

UR - http://www.scopus.com/inward/record.url?scp=85122675723&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.20996

DO - 10.1001/jama.2021.20996

M3 - Letter

C2 - 34982126

AN - SCOPUS:85122675723

VL - 327

SP - 83

EP - 84

JO - JAMA

JF - JAMA

SN - 0098-7484

IS - 1

ER -

To the editor

Access to Document

Other files and links

Cite this